157 related articles for article (PubMed ID: 32230714)
1. ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen.
Sieuwerts AM; Inda MA; Smid M; van Ooijen H; van de Stolpe A; Martens JWM; Verhaegh WFJ
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32230714
[No Abstract] [Full Text] [Related]
2. SIAH2 protein expression in breast cancer is inversely related with ER status and outcome to tamoxifen therapy.
van der Willik KD; Timmermans MM; van Deurzen CH; Look MP; Reijm EA; van Zundert WJ; Foekens R; Trapman-Jansen AM; den Bakker MA; Westenend PJ; Martens JW; Berns EM; Jansen MP
Am J Cancer Res; 2016; 6(2):270-84. PubMed ID: 27186402
[TBL] [Abstract][Full Text] [Related]
3. Enabling precision medicine by unravelling disease pathophysiology: quantifying signal transduction pathway activity across cell and tissue types.
van de Stolpe A; Holtzer L; van Ooijen H; Inda MA; Verhaegh W
Sci Rep; 2019 Feb; 9(1):1603. PubMed ID: 30733525
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
Chang SB; Miron P; Miron A; Iglehart JD
J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
[TBL] [Abstract][Full Text] [Related]
5. Signal Transduction Pathway Activity in High-Grade, Serous Ovarian Carcinoma Reveals a More Favorable Prognosis in Tumors with Low PI3K and High NF-κB Pathway Activity: A Novel Approach to a Long-Standing Enigma.
van Lieshout L; van de Stolpe A; van der Ploeg P; Bowtell D; de Hullu J; Piek J
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32961868
[TBL] [Abstract][Full Text] [Related]
6. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
7. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer.
Zhou Y; Yau C; Gray JW; Chew K; Dairkee SH; Moore DH; Eppenberger U; Eppenberger-Castori S; Benz CC
BMC Cancer; 2007 Apr; 7():59. PubMed ID: 17407600
[TBL] [Abstract][Full Text] [Related]
8. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
9. Using second harmonic generation to predict patient outcome in solid tumors.
Burke K; Smid M; Dawes RP; Timmermans MA; Salzman P; van Deurzen CH; Beer DG; Foekens JA; Brown E
BMC Cancer; 2015 Nov; 15():929. PubMed ID: 26603532
[TBL] [Abstract][Full Text] [Related]
10. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Look MP; Peters HA; van Putten WL; Portengen H; Klijn JG
J Natl Cancer Inst; 1995 May; 87(10):751-6. PubMed ID: 7563153
[TBL] [Abstract][Full Text] [Related]
11. In vivo prediction of response to antiestrogen treatment in estrogen receptor-positive breast cancer.
Bennink RJ; van Tienhoven G; Rijks LJ; Noorduyn AL; Janssen AG; Sloof GW
J Nucl Med; 2004 Jan; 45(1):1-7. PubMed ID: 14734659
[TBL] [Abstract][Full Text] [Related]
12. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
Carlson RW; Henderson IC
Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
[TBL] [Abstract][Full Text] [Related]
13. Androgen Receptor Pathway Activity Assay for Sepsis Diagnosis and Prediction of Favorable Prognosis.
Bouwman W; Verhaegh W; van de Stolpe A
Front Med (Lausanne); 2021; 8():767145. PubMed ID: 34888328
[No Abstract] [Full Text] [Related]
14. GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease.
Liu J; Prager-van der Smissen WJ; Look MP; Sieuwerts AM; Smid M; Meijer-van Gelder ME; Foekens JA; Hollestelle A; Martens JW
Cancer Lett; 2016 Jun; 376(1):104-9. PubMed ID: 27018307
[TBL] [Abstract][Full Text] [Related]
15. Impact of androgen receptor expression in fluoxymesterone-treated estrogen receptor-positive metastatic breast cancer refractory to contemporary hormonal therapy.
Kono M; Fujii T; Lyons GR; Huo L; Bassett R; Gong Y; Karuturi MS; Tripathy D; Ueno NT
Breast Cancer Res Treat; 2016 Nov; 160(1):101-109. PubMed ID: 27663436
[TBL] [Abstract][Full Text] [Related]
16. ERRγ target genes are poor prognostic factors in Tamoxifen-treated breast cancer.
Madhavan S; Gusev Y; Singh S; Riggins RB
J Exp Clin Cancer Res; 2015 May; 34(1):45. PubMed ID: 25971350
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic targeting in the estrogen receptor hormonal pathway.
Katzenellenbogen BS; Frasor J
Semin Oncol; 2004 Feb; 31(1 Suppl 3):28-38. PubMed ID: 15052541
[TBL] [Abstract][Full Text] [Related]
18. First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer.
Peron J; Tredan O; Ray-Coquard I; Bachelot T; Labidi Galy SI; Favier B; Treilleux I; Guastalla JP
Bull Cancer; 2012 Feb; 99(2):E18-25. PubMed ID: 22257781
[TBL] [Abstract][Full Text] [Related]
19. Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.
Foekens JA; Portengen H; Look MP; van Putten WL; Thirion B; Bontenbal M; Klijn JG
Br J Cancer; 1994 Dec; 70(6):1217-23. PubMed ID: 7981080
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer.
Yamashita H; Yando Y; Nishio M; Zhang Z; Hamaguchi M; Mita K; Kobayashi S; Fujii Y; Iwase H
Breast Cancer; 2006; 13(1):74-83. PubMed ID: 16518065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]